Estimated Average Glucose Calculator
Free Estimated average glucose Calculator with medically-sourced formulas. Enter your measurements for personalized, accurate health insights.
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist
Medical disclaimer: This calculator is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results are general estimates and may not reflect your individual circumstances. Always consult a qualified healthcare professional before making decisions about your health.
Estimated Average Glucose Calculator
Calculator
Adjust values & calculateEnter your values below. Every result is computed in your browser — no data is sent to any server.
Formula: eAG (mg/dL) = 28.7 x HbA1c - 46.7 | eAG (mmol/L) = 1.59 x HbA1c - 2.59
Worked example — eAG: 148.5 mg/dL (8.24 mmol/L) | At ADA Target (<7%) | Prediabetes-Diabetes border | Good control
Formula
eAG (mg/dL) = 28.7 x HbA1c - 46.7 | eAG (mmol/L) = 1.59 x HbA1c - 2.59
The ADAG (A1c-Derived Average Glucose) formula was derived from a study of 507 participants using continuous glucose monitoring. It converts the HbA1c percentage to an estimated average glucose that corresponds to the mean glucose over the prior 2-3 months. The IFCC conversion is: mmol/mol = (NGSP% - 2.15) x 10.929.
Worked Examples
Example 1: Well-Controlled Diabetes Assessment
Problem:A patient with Type 2 diabetes has an HbA1c of 6.8%. Their home glucose readings show fasting of 110 mg/dL and post-meal of 145 mg/dL. Calculate eAG and assess control.
Solution:eAG (ADAG formula) = 28.7 x 6.8 - 46.7 = 195.16 - 46.7 = 148.5 mg/dL eAG in mmol/L = 148.5 / 18.0182 = 8.24 mmol/L IFCC A1c = (6.8 - 2.15) x 10.929 = 50.8 mmol/mol Home average = (110 + 145) / 2 = 127.5 mg/dL Discrepancy = 127.5 - 148.5 = -21.0 mg/dL (home readings lower than eAG) A1c target assessment: 6.8% is below 7.0% target Estimated time in range: approximately 73%
Result:eAG: 148.5 mg/dL (8.24 mmol/L) | At ADA Target (<7%) | Prediabetes-Diabetes border | Good control
Example 2: Poorly Controlled Diabetes Assessment
Problem:A patient has HbA1c of 9.5%. Home fasting glucose averages 200 mg/dL and post-meal 280 mg/dL. Calculate eAG and determine management implications.
Solution:eAG (ADAG formula) = 28.7 x 9.5 - 46.7 = 272.65 - 46.7 = 226.0 mg/dL eAG in mmol/L = 226.0 / 18.0182 = 12.54 mmol/L IFCC A1c = (9.5 - 2.15) x 10.929 = 80.3 mmol/mol Home average = (200 + 280) / 2 = 240.0 mg/dL Discrepancy = 240.0 - 226.0 = +14.0 mg/dL (home readings slightly higher) A1c target: 9.5% is 2.5% above 7.0% target Estimated time in range: approximately 22%
Result:eAG: 226.0 mg/dL (12.54 mmol/L) | 2.5% above target | Urgent medication intensification needed
Frequently Asked Questions
What is estimated average glucose and how is it calculated from HbA1c?
Estimated average glucose (eAG) is a calculation that converts the HbA1c percentage into an approximate average blood glucose value in mg/dL or mmol/L, making HbA1c results more intuitive for patients and clinicians. The ADAG (A1c-Derived Average Glucose) study, published in 2008, established the definitive relationship using continuous glucose monitoring data from 507 participants across 10 international centers. The resulting formula is eAG (mg/dL) = 28.7 multiplied by HbA1c minus 46.7, or equivalently eAG (mmol/L) = 1.59 multiplied by HbA1c minus 2.59. For example, an HbA1c of 7.0% corresponds to an eAG of approximately 154 mg/dL (8.6 mmol/L). This conversion helps bridge the communication gap between the laboratory measurement (HbA1c) and the daily glucose values that patients monitor at home.
How does HbA1c reflect blood sugar control over time?
Hemoglobin A1c measures the percentage of hemoglobin molecules in red blood cells that have glucose permanently attached to them through a process called glycation. Since red blood cells have an average lifespan of approximately 120 days (about 3 to 4 months), the HbA1c value reflects the cumulative glucose exposure over this period. However, more recent glucose levels have a disproportionately greater influence on the HbA1c result. Studies estimate that approximately 50 percent of the HbA1c value reflects blood glucose from the most recent 30 days, about 25 percent from the preceding 30 to 60 days, and 25 percent from days 60 to 120. This means that significant changes in glucose control will begin to affect HbA1c within a few weeks, though the full impact takes approximately 3 months to be reflected. This weighting explains why HbA1c can change relatively quickly after initiating new diabetes medications.
What is the IFCC HbA1c standard and how does it differ from the NGSP percentage?
Two different standardization systems exist for reporting HbA1c values. The NGSP (National Glycohemoglobin Standardization Program) system, used primarily in the United States, reports HbA1c as a percentage (for example, 7.0%). The IFCC (International Federation of Clinical Chemistry) system, used in many other countries, reports HbA1c in millimoles per mole (mmol/mol). The conversion formula is IFCC (mmol/mol) = (NGSP percentage - 2.15) multiplied by 10.929. So an NGSP value of 7.0% equals approximately 53 mmol/mol in the IFCC system. The IFCC method measures a specific molecular species of glycated hemoglobin using a more precise reference method. Many countries now report both values simultaneously to avoid confusion. Understanding this conversion is essential for interpreting medical literature from different countries and for patients who travel internationally.
What factors can cause HbA1c to be inaccurate or misleading?
Several conditions can make HbA1c an unreliable indicator of average glucose, leading to either falsely high or falsely low values. Conditions that falsely lower HbA1c include hemolytic anemias, chronic kidney disease (due to shortened red blood cell lifespan), blood loss, blood transfusions, sickle cell disease and other hemoglobin variants, and pregnancy. Conditions that falsely raise HbA1c include iron deficiency anemia, vitamin B12 deficiency, splenectomy (prolonged red blood cell survival), and heavy alcohol use. Racial and ethnic differences in HbA1c have also been documented, with studies showing that African American individuals may have HbA1c values 0.4 percentage points higher than Caucasian individuals at the same average glucose level. When HbA1c accuracy is questioned, fructosamine or glycated albumin can serve as alternative markers of glycemic control over shorter timeframes of 2 to 3 weeks.
What are the recommended HbA1c targets for different patient populations?
HbA1c targets are individualized based on patient characteristics and clinical context. The American Diabetes Association recommends a general target of less than 7.0% for most non-pregnant adults with diabetes, as this level has been shown to reduce microvascular complications. More stringent targets of less than 6.5% may be appropriate for selected individuals with short diabetes duration, long life expectancy, no significant cardiovascular disease, and low hypoglycemia risk. Less stringent targets of less than 8.0% are recommended for patients with history of severe hypoglycemia, limited life expectancy, advanced complications, extensive comorbidities, or long-standing diabetes where the 7% target is difficult to achieve despite adequate medication and self-management. For pregnant women with pre-existing diabetes, the target is less than 6.0% to 6.5% if achievable without significant hypoglycemia. Older adults may have targets of less than 7.5% to 8.5% depending on functional status.
How does estimated time in range relate to HbA1c values?
Time in range (TIR) is a newer metric from continuous glucose monitoring that measures the percentage of time glucose values stay between 70 and 180 mg/dL (3.9 to 10.0 mmol/L). Research has established an approximate correlation between TIR and HbA1c. A TIR of 70% (the recommended target for most adults with diabetes) corresponds roughly to an HbA1c of 7.0%. Each 10 percentage point increase in TIR corresponds to approximately 0.5% decrease in HbA1c. For example, TIR of 50% approximates HbA1c of 8.0%, while TIR of 80% approximates 6.5%. However, this relationship is imperfect because two patients with identical HbA1c values can have very different TIR percentages due to differences in glucose variability. A patient with wide glucose swings (high glycemic variability) may have the same HbA1c as a patient with stable glucose but very different TIR and clinical outcomes.
Why might there be a discrepancy between home glucose readings and eAG from HbA1c?
Discrepancies between home glucose monitoring averages and eAG derived from HbA1c are extremely common and have multiple explanations. First, fingerstick testing typically captures only 4 to 8 daily snapshots while HbA1c reflects the entire 24-hour glucose profile including overnight values that patients rarely measure. Second, most patients test preferentially before meals (when glucose tends to be lower) and may miss significant post-meal spikes. Third, biological variation in glycation rates means some individuals are high glycators who attach glucose to hemoglobin more readily, producing higher HbA1c relative to their actual average glucose. Conversely, low glycators have lower HbA1c than expected. Fourth, the conditions mentioned previously (anemia, hemoglobin variants, kidney disease) can skew HbA1c. When discrepancies are consistently large, clinicians should consider CGM data, fructosamine testing, or glycated albumin as complementary measures of glycemic control.
How often should HbA1c be measured and what constitutes a meaningful change?
The American Diabetes Association recommends HbA1c testing at least twice yearly for patients meeting treatment goals with stable glycemic control, and quarterly for patients whose therapy has changed or who are not meeting glycemic goals. After a medication change, waiting at least 8 to 12 weeks before rechecking HbA1c is advisable because a shorter interval may not reflect the full effect of the intervention. Regarding meaningful change, the analytical variability of the HbA1c assay is approximately 0.3 to 0.5 percentage points, meaning changes smaller than this may represent laboratory variation rather than true clinical change. A decrease of 0.5% or more is generally considered clinically meaningful. Point-of-care HbA1c testing is now widely available and provides results within minutes, facilitating real-time clinical decision-making during office visits. However, point-of-care assays may have slightly wider variability than laboratory-based methods.
What is the relationship between HbA1c reduction and diabetes complication prevention?
Landmark clinical trials have established clear relationships between HbA1c reduction and diabetes complication prevention. The DCCT (Diabetes Control and Complications Trial) in Type 1 diabetes showed that lowering HbA1c from 9.0% to 7.0% reduced the risk of retinopathy by 76%, nephropathy by 50%, and neuropathy by 60%. The UKPDS (UK Prospective Diabetes Study) in Type 2 diabetes demonstrated that each 1% reduction in HbA1c was associated with 21% reduction in diabetes-related deaths, 14% reduction in myocardial infarction, and 37% reduction in microvascular complications. The relationship is not linear but appears to follow a continuous curve, with the greatest absolute risk reduction occurring at higher baseline HbA1c values. However, the ACCORD, ADVANCE, and VADT trials showed that very aggressive glucose lowering in high-risk patients with established cardiovascular disease may not provide macrovascular benefits and can increase hypoglycemia risk.
How do newer diabetes medications affect HbA1c and what reductions can be expected?
Different classes of diabetes medications produce varying degrees of HbA1c reduction. Metformin, the first-line therapy, typically lowers HbA1c by 1.0 to 1.5 percentage points. Sulfonylureas achieve similar reductions of 1.0 to 1.5 points but carry higher hypoglycemia risk. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower HbA1c by 0.5 to 0.8 points while also providing cardiovascular and renal benefits independent of glucose lowering. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are among the most potent oral and injectable non-insulin agents, reducing HbA1c by 1.0 to 1.8 points with additional weight loss benefits. Tirzepatide, a dual GIP/GLP-1 agonist, has shown HbA1c reductions of up to 2.0 to 2.5 points in clinical trials. Insulin therapy provides the most flexible and potent glucose lowering with essentially unlimited HbA1c reduction potential, limited only by hypoglycemia risk. Combination therapy using multiple mechanisms typically produces additive HbA1c reductions.
References
- Nathan DM et al. Translating the A1C Assay Into Estimated Average Glucose Values - Diabetes Care 2008
- American Diabetes Association - Glycemic Targets: Standards of Care in Diabetes 2024
- Bergenstal RM et al. Glucose Management Indicator: A New Term for Estimating A1C From Continuous Glucose Monitoring
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist · Editorial policy
Related Calculators
🧮A1c to Blood Glucose Calculator
Convert A1C percentage to estimated average blood glucose (eAG) in mg/dL or mmol/L.
🧮Menstrual Cycle Length Calculator
Calculate your average menstrual cycle length from tracking the last several periods.
🧮Insulin Dose Calculator
Calculate insulin dose based on carb intake, correction factor, and current blood glucose.
🧮Addiction Calculator
Calculate addiction with inputs, formulas, and instant results.
🧮Alcohol Unit Calculator
Calculate alcohol unit with inputs, formulas, and instant results.
🧮AUDIT-C Calculator
Calculate audit ccalculator with inputs, formulas, and instant results.
🧮AUDIT Full Questionnaire Calculator
Calculate auditfull questionnaire with inputs, formulas, and instant results.
🧮AUDIT Score Calculator
Calculate audit score with inputs, formulas, and instant results.